Abstract
ABSTRACT
Background: Soft tissue tumors represent a relatively common and heterogeneous group of lesions characterized by diverse yet nonspecific clinical manifestations. Although histopathology remains the diagnostic gold standard, the application of advanced techniques such as immunohistochemistry is indispensable to ensure the accurate diagnosis with the latest WHO classification. Objectives: (1) To describe clinical characteristics and the histopathological classification of soft tissue tumors. (2) To evaluate the expression of immunohistochemical markers in soft tissue tumors. Materials and methods: A cross-sectional study was conducted on 166 patients diagnosed with soft tissue t umors between 04/2025 and 01/2026 at Hue University of Medicine and Pharmacy Hospital. Results: Malignant soft tissue tumors accounted for 21.1% of cases. The majority presented with a single lesion (91.6%), most commonly located in the superficial trunk (34.4%). Tumors smaller than 5 cm comprised 68.1% of cases. Adipocytic tumors were the most frequent (42.8%). Lipoma and hemangioma were predominant in the benign group (53,4% and 15,5%), fibrohistiocytoma in the borderline group (61,5%), and fibrosarcoma in the malignant group (22,7%). Immunohistochemistry revealed the expression of characteristic markers that supported the diagnostic classification, Vimentine (+) 100%, Desmine (+) 5/5 cases and SMA (+) 3/5 cases for smooth tumours, CD68 (+) 100% for fibrohistiocytic tumours, CD34 (+) for vascular and the other tumours.. Conclusion: Malignant soft tissue tumors accounted for 21.1% of cases. Besides histopathology, immunohistochemistry revealed the expression of characteristic markers that supported the key role for the classification of tumour types.
Keywords: soft tissue tumours, histopathology, clinical characteristics, immunohistochemistry
| Published | 2026-04-30 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | Vol. 16 No. 02 (2026) | |
| Section | Original Articles | |
| DOI | 10.34071/jmp.2026.2.921 | |
| Keywords |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2026 Hue Journal of Medicine and Pharmacy
References
Goldblum JR, Weiss SW, Folpe AL. Enzinger and Weiss's soft tissue tumors E-Book: Elsevier Health Sciences; 2013.
Myhre-Jensen O. A consecutive 7-year series of 1331 benign soft tissue tumours: clinicopathologic data. Comparison with sarcomas. Acta Orthopaedica Scandinavica. 1981;52(3):287-93.
Gatta G, Capocaccia R, Botta L, Mallone S, De Angelis R, Ardanaz E, et al. Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet—a population-based study. The Lancet Oncology. 2017;18(8):1022-39.
Von Mehren M, Randall RL, Benjamin RS, Boles S, Bui MM, Ganjoo KN, et al. Soft tissue sarcoma, version 2.2018, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network. 2018;16(5):536-63.
Kao EY, Mantilla JG. What’s new in soft tissue and bone pathology 2022–updates from the WHO classification 5th edition. Journal of Pathology and Translational Medicine. 2022;56(6):385.
Yang Z, Zheng R, Zhang S, Zeng H, Li H, Chen W. Incidence, distribution of histological subtypes and primary sites of soft tissue sarcoma in China. Cancer biology & medicine. 2019;16(3):565-74.
Vhriterhire RA, Ngbea JA, Akpor IO. Histological spectrum of soft-tissue tumors in a tertiary hospital. Sahel Medical Journal. 2020;23(3):170-8.
Kransdorf MJ. Benign soft-tissue tumors in a large referral population: distribution of specific diagnoses by age, sex, and location. AJR American journal of roentgenology. 1995;164(2):395-402.
Gutmann DH, Ferner RE, Listernick RH, Korf BR, Wolters PL, Johnson KJ. Neurofibromatosis type 1. Nature Reviews Disease Primers. 2017;3(1):1-17.
Gassert FG, Gassert FT, Specht K, Knebel C, Lenze U, Makowski MR, et al. Soft tissue masses: distribution of entities and rate of malignancy in small lesions. Bmc Cancer. 2021;21(1):93.
Ilaslan H, Schils J, Nageotte W, Lietman SA, Sundaram M. Clinical presentation and imaging of bone and soft-tissue sarcomas. Cleveland Clinic journal of medicine. 2010;77(1):S2.
Singh HP, Grover S, Garg B, Sood N. Histopathological spectrum of soft-tissue tumors with immunohistochemistry correlation and FNCLCC grading: A North Indian Experience. Nigerian Medical Journal. 2017;58(5):149-55.
Ng sr. Soft ti ssue tumour resection structured reporti ng protocol 1 st Edition (2011). 2011.
Agravat A, Dhruva G, Parmar S. Histopathology Study of Human's Soft Tissue Tumours and Tumour Like Lesions. Journal of cell and Tissue Research. 2010;10(2):2287.
Hung ND, Anh HM, Hang DT. Superficial soft tissue tumors: the relationship of the tumor with fascia on magnetic resonance imaging in the differential diagnosis of benign and malignant lesions. Vietnam medical journal. 2025;550(3).
Kim DH, Murovic JA, Tiel RL, Moes G, Kline DG. A series of 397 peripheral neural sheath tumors: 30-year experience at Louisiana State University Health Sciences Center. Journal of neurosurgery. 2005;102(2):246-55.
Jonczak E, Grossman J, Alessandrino F, Seldon Taswell C, Velez-Torres JM, Trent J. Liposarcoma: a journey into a rare tumor’s epidemiology, diagnosis, pathophysiology, and limitations of current therapies. Cancers. 2024;16(22):3858.
Yusuf I, Mohammed AZ, Iliyasu Y. Histopathological study of soft tissue sarcomas seen in a teaching hospital in Kano, Nigeria. Nigerian Journal of Basic and Clinical Sciences. 2013;10(2):70-5.
Zhang L, Akiyama T, Fukushima T, Iwata S, Tsuda Y, Takeshita K, et al. Prognostic factors and impact of surgery in patients with metastatic soft tissue sarcoma at diagnosis: a population-based cohort study. Japanese Journal of Clinical Oncology. 2021;51(6):918-26.
Dabbs D.J. (2019), Diagnostic Immunohistochemistry, Theranostic and Genomic Applications, 5th Edition, Elsevier, Philadelphia , USA.